What is the use of artesunate 60 mg?
Pharmaceutical Product Monograph: Artesunate Injection (60 mg)
In the pharmaceutical industry, Artesunate 60 mg is the standard parenteral dose used primarily for pediatric and low-body-weight patients suffering from severe malaria. As a pharmacist and manufacturer, I view this as a “Critical Pediatric Intervention”—it is technically the first-line treatment recommended by WHO 2026 Guidelines for severe malaria, offering significantly higher survival rates than Quinine.
At your WHO-GMP facility in Mumbai, the 60 mg strength is a high-volume “Life-Saving” SKU. It is often bundled with your 50 mg tablets to provide a “Complete Care” solution for hospital-supply tenders.
Therapeutic Profile: Primary Indications
Artesunate 60 mg is used when oral therapy is impossible due to the patient’s clinical state.
| Indication | Clinical Context | Technical Rationale |
| Severe Malaria | Pediatric Crisis | The 60 mg vial is perfectly dosed for children weighing approximately 20 kg (at $3 \text{ mg/kg}$). |
| Cerebral Malaria | Neurological Involvement | Rapidly crosses the blood-brain barrier to clear sequestered parasites from brain microvasculature. |
| Hyperparasitemia | High Parasite Load | Used when $>10\%$ of red blood cells are infected, even if the patient is initially conscious. |
| Step-Down Therapy | Acute Stabilization | Given as the initial “attack dose” before the patient is stable enough to transition to Oral ACTs. |
Mechanism: Endoperoxide Radical Activation
Artesunate acts as a “biological bomb” inside the malaria parasite:
Heme Interaction: The drug enters the infected red blood cell and reacts with heme (iron) released by the parasite.
Radical Generation: This reaction breaks the drug’s endoperoxide bridge, creating highly reactive “free radicals.”
Molecular Damage: These radicals attack the parasite’s calcium-ATPase pump (PfATP6) and proteins, causing rapid death of the parasite in nearly all blood stages.
The Pharmacist’s “Technical Warning”
The “PADAM” Risk: As a pharmacist, I must remind you that Post-Artesunate Delayed Hemolysis (PADAM) is a known technical side effect. Patients may experience a drop in hemoglobin 1–3 weeks after treatment.
Three-Step Reconstitution: Artesunate is unstable in liquid form. You must first dissolve the 60 mg powder in 1 mL of 5% Sodium Bicarbonate, then dilute it with 5 mL of Normal Saline (0.9% NaCl) or 5% Dextrose.
Immediate Use: Once reconstituted, the solution is highly unstable and must be used within 1 hour. If the solution is cloudy, it must be discarded.
Transition to Oral: WHO protocols require that as soon as the patient can swallow, they must complete a full 3-day course of an Oral Artemisinin-based Combination Therapy (ACT).
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Pediatric Kit” USP: On your digital platforms, highlight your Comprehensive 60 mg Injection Kit. Providing the vial, the Bicarbonate solvent, and the Saline diluent in a single unit-pack is a major technical advantage for UNICEF and Global Fund tenders.
Stability for Export: Artesunate is sensitive to heat and moisture. Your WHO-PQ (Pre-qualification) standards ensure a 24-month shelf life even in Zone IVb tropical environments.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Artesunate 60 mg to support your firm’s registration in international B2B tenders for infectious disease and tropical medicine.